Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Investigating the role of metformin on cardiac fibrosis in plasminogen activator inhibitor-1 deficient mice
FY 2021-22
Summary
Loss of critical heart cells and the associated reduction in heart contraction are defining features of heart dysfunction in aging and after a serious cardiovascular event. Plasminogen activator inhibitor-1 (PAI-1) is a protein that has a known role in the process of blood clotting. It is well understood that low levels of Pai-1 cause bleeding disorders. Studies in mice lacking Pai-1 show spontaneous cardiac impairment in response to aging. These results are also observed within the Berne Amish community, which has an increase in individuals lacking Pai-1, and they experience accelerated cardiac disease. Metformin is drug administered to patients with diabetes which has a strong safety record and sugar-lowering function. Metformin treatment also improves cardiac impairment and can reduce cardiac damage in response to a form of surgery that causes cardiac stress. Under conditions where levels of Pai-1 are low, cardiac damage increases during aging or under cardiac stress and impairs cardiac healing. Thus, we hypothesize treatment of mice lacking Pai-1 with metformin will reduce cardiac damage and improve heart function. Aim one will investigate if mice lacking Pai-1 treated with metformin have reduced spontaneous development of cardiac damage associated with aging. Aim two will investigate if mice lacking Pai-1 treated with metformin have reduced cardiac damage in response to two models of cardiac stress, (i) a form of surgery and (2) inducing a high blood pressure state. In both aims, heart function will be assessed via ultrasound and damage (scarring) will be assessed using other techniques. These experiments will add significantly to the cardiovascular impact of metformin in a setting of low Pai-1 levels.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467039
Name
Pulente Serena M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of metformin on cardiac fibrosis in plasminogen activator inhibitor-1 deficient mice
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Cardiac Fibrosis; Cardiac Remodeling; Echocardiography; Heart Failure; Hypertension; Hypertrophy; Metformin; Plasminogen Activator Inhibitor-1; Transverse Aortic Constriction Surgery
Abstract
Loss of critical heart cells and the associated reduction in heart contraction are defining features of heart dysfunction in aging and after a serious cardiovascular event. Plasminogen activator inhibitor-1 (PAI-1) is a protein that has a known role in the process of blood clotting. It is well understood that low levels of Pai-1 cause bleeding disorders. Studies in mice lacking Pai-1 show spontaneous cardiac impairment in response to aging. These results are also observed within the Berne Amish community, which has an increase in individuals lacking Pai-1, and they experience accelerated cardiac disease. Metformin is drug administered to patients with diabetes which has a strong safety record and sugar-lowering function. Metformin treatment also improves cardiac impairment and can reduce cardiac damage in response to a form of surgery that causes cardiac stress. Under conditions where levels of Pai-1 are low, cardiac damage increases during aging or under cardiac stress and impairs cardiac healing. Thus, we hypothesize treatment of mice lacking Pai-1 with metformin will reduce cardiac damage and improve heart function. Aim one will investigate if mice lacking Pai-1 treated with metformin have reduced spontaneous development of cardiac damage associated with aging. Aim two will investigate if mice lacking Pai-1 treated with metformin have reduced cardiac damage in response to two models of cardiac stress, (i) a form of surgery and (2) inducing a high blood pressure state. In both aims, heart function will be assessed via ultrasound and damage (scarring) will be assessed using other techniques. These experiments will add significantly to the cardiovascular impact of metformin in a setting of low Pai-1 levels.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pulente, Serena M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~